NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (TSX-V: NBY) (“NioBay” or the “Corporation”), is pleased to announce the closing of its previously announced “best efforts” private placement (the “Brokered Offering”) for aggregate gross proceeds of C$8,497,990.20, which includes the exercise of the agent’s option. The Brokered Offering is comprised of the sale of (i) 12,277,430 units of the Corpo ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.Shares of Lennar Corp (NYSE:LEN) fell sharply in pre-market trading after the company reported mixed financial results for the fourth quarter.Lennar reported fourth-quarter revenue of $9.37 billion, beating analyst estimates of $9.02 billion, according to Benzinga Pro. The company reported adjusted earnings of $2.03 per share for the quarter, missing estimates of $2.21 per share.Lennar shares dipped 3.8% to $1 ...

Group 1 - U.S. stocks experienced a decline, with the Dow Jones index dropping over 100 points on Tuesday [1] - Cementos Pacasmayo SAA – ADR shares surged 47.4% to $10.30 following Holcim's agreement to acquire 50.01% of its owner, Inversiones Aspi. S.A. [1] Group 2 - Rezolve AI PLC reported preliminary December revenue results, leading to a 23.7% increase in its stock price to $2.87 [2] - Emerald Holding Inc announced a review of potential strategic options, resulting in a 17% rise in its stock price to $4.14 [2] - NovaBay Pharmaceuticals Inc's stock increased by 16.2% to $3.15 [2] - Tilray Brands Inc saw a 15% surge in its stock price to $12.57 [2] - Clearpoint Neuro Inc's stock jumped 14.2% to $14.14 [2] - Fermi Inc gained 11.4%, reaching $9.57 [2] - Sezzle Inc authorized a $100 million stock buyback, leading to a 9.6% increase in its stock price to $72.49 [2] - WW International Inc launched a new platform for the GLP-1 era, resulting in a 7.8% gain to $26.19 [2] - Circle Internet Group Inc rose 7.7% to $81.24 [2] - Lemonade Inc's stock surged 7.4% to $80.59 [2] - Netskope Inc gained 6.9%, reaching $20.37 [2] - Ascentage Pharma Group International's stock rose 6% to $29.26 [2] - RH's stock increased by 5.5% to $172.60, with Barclays analyst maintaining an Overweight rating and lowering the price target from $385 to $283 [2] - Affirm Holdings Inc gained 4.4%, reaching $68.56 [2]

Group 1 - U.S. stocks showed mixed performance, with the Dow Jones increasing by over 600 points on Thursday [1] - Diamond Hill Investment Group Inc's shares surged 45.3% to $170.74 after First Eagle announced an acquisition for $175 per share in a $473 million all-cash deal [1] Group 2 - Planet Labs PBC's stock rose 29.7% to $16.79 following better-than-expected third-quarter sales results and an optimistic fourth-quarter sales guidance [2] - Nextdoor Holdings Inc experienced a gain of 22.9% to $3.11 [2] - Gemini Space Station Inc's shares jumped 19.2% to $13.54 after regulatory approval for its subsidiary to offer prediction markets to U.S. customers [2] - Rhythm Pharmaceuticals Inc's stock increased by 13.5% to $119.00 after announcing preliminary results from a Phase 2 trial for setmelanotide in Prader-Willi syndrome patients [2] - Candel Therapeutics Inc gained 12.4% to $6.52 [2] - VersaBank's shares rose 12.34% to $14.52 [2] - Perpetua Resources Corp's stock increased by 10.4% to $28.37 [2] - iHeartMedia Inc jumped 10.1% to $5.19 [2] - NovaBay Pharmaceuticals Inc gained 9.5% to $2.65 [2] - Idaho Strategic Resources Inc's shares rose 9.3% to $43.62 [2] - Immunovant Inc's stock increased by 8.5% to $25.57 after pricing a $550 million common stock offering [2] - Vail Resorts Inc gained 8.3% to $153.30 following first-quarter results [2] - Mosaic Co's shares surged 7.2% to $25.47 amid higher fertilizer stock prices after reports of Ukraine attacking Russian fertilizer plants [2] - Wayfair Inc's stock rose 6.9% to $99.76 [2] - Centene Corp gained 5.3% to $40.72 [2]

Core Viewpoint - NioBay Metals Inc. has increased the maximum gross proceeds of its private placement from C$5,000,000 to C$7,500,000 due to strong investor demand [1] Group 1: Offering Details - The Marketed Offering consists of Units, FT Units, and Charity FT Units, with each Unit comprising one common share and one warrant [2] - The FT Units will be sold at C$0.16 each, while Charity FT Units will be priced at C$0.21 each [8] - Red Cloud Securities Inc. is acting as the sole agent and bookrunner for the Offering, with an option to sell an additional C$1,000,000 in securities [3] Group 2: Use of Proceeds - The net proceeds from the Offering will be used for the exploration and advancement of the James Bay Niobium Project, as well as for working capital and general corporate purposes [4] - Gross proceeds from the sale of FT Shares will be allocated to eligible Canadian exploration expenses related to the James Bay Niobium Project [5] Group 3: Regulatory and Compliance - The Offering will comply with applicable regulatory requirements and will be offered in several Canadian provinces under the Listed Issuer Financing Exemption [6] - The securities will be immediately freely tradeable in Canada, while those not issued under the Listed Issuer Financing Exemption will have a hold period of four months plus one day [7] Group 4: Company Background - NioBay aims to lead in low carbon consumption mining practices and emphasizes the importance of Indigenous community participation in its operations [12] - The company holds a 100% interest in the James Bay Niobium Project and a 72.5% interest in the Crevier Niobium and Tantalum project [12] Group 5: Industry Context - Niobium is a highly resistant metal used in various sectors, enhancing material properties and reducing environmental impacts [13]

Core Viewpoint - NioBay Metals Inc. has announced a private placement agreement with Red Cloud Securities Inc. to raise up to C$5,000,000 for its James Bay Niobium Project and general corporate purposes [1][4]. Group 1: Offering Details - The private placement will consist of Units, FT Units, and Charity FT Units, with each Unit comprising one common share and one warrant [2][3]. - The pricing for the Units is set at C$0.14, FT Units at C$0.16, and Charity FT Units at C$0.21 [8]. - An additional option allows Red Cloud to sell up to C$1,000,000 in any combination of Units, FT Units, and Charity FT Units prior to the closing [3]. Group 2: Use of Proceeds - The net proceeds from the Offering will be allocated to the exploration and advancement of the James Bay Niobium Project, as well as for working capital and general corporate purposes [4]. - Proceeds from the sale of FT Shares will specifically be used for eligible Canadian exploration expenses related to the James Bay Niobium Project [5]. Group 3: Regulatory and Compliance - The Offering will comply with applicable regulatory requirements and will be offered in several Canadian provinces under the Listed Issuer Financing Exemption [6][7]. - The Offering is scheduled to close on December 18, 2025, subject to necessary regulatory approvals [10]. Group 4: Company Overview - NioBay aims to lead in low carbon consumption mining practices while ensuring the participation of Indigenous communities in its operations [12]. - The company holds a 100% interest in the James Bay Niobium Project and a 72.5% interest in the Crevier Niobium and Tantalum project [12]. Group 5: Industry Context - Niobium is a highly valuable metal used in various sectors, enhancing material properties and reducing environmental impacts [13].

Core Points - KALA BIO Inc. experienced a significant stock price increase of 37.87% to $0.88 in after-hours trading, following a regular session close at $0.64, which was a 3.45% increase [1][6] Financing and Agreements - KALA BIO entered into a Securities Purchase Agreement with investor David Lazar to raise up to $6 million through a private placement, as disclosed in an SEC Form 8-K filing [2] - The first closing raised $1.8 million from the sale of 900,000 Series AA Preferred Shares at $2 each, while a second closing is expected to raise $4.2 million through 2.1 million Series AAA Preferred Shares at $2 each, pending stockholder approval [3] Loan Settlement - KALA BIO reached a loan settlement agreement with Oxford Finance LLC, which requires a $2 million cash payment and the issuance of 1.62 million common stock shares [4] - Upon completion of an initial $1 million payment by January 15, 2026, or the stockholder meeting date, and stock issuance, the Loan Agreement balance will be reduced by $7 million [4] Leadership Changes - David Lazar was appointed as Chief Executive Officer and Principal Executive Officer by the Board, effective from the first closing of the financing [5] - Lazar previously served as CEO of Novabay Pharmaceuticals Inc. from August to November [5] Stock Performance - KALA BIO's stock has declined 91.72% year to date, with a 52-week range of $0.61 to $20.58 and a market capitalization of $5.21 million [6] - Benzinga's Edge Stock Rankings indicate a negative price trend for KALA stock across all time frames [6]

Core Insights - NioBay Metals Inc. has announced successful results from its 2025 summer drill campaign at the Crevier niobium and tantalum project, confirming mineralized zones over a strike length exceeding 6 km [1][3][4] - The company plans to conduct a significantly larger pilot test of 140 tonnes, compared to the previous 10-tonne test, and is engaging with potential customers for niobium oxide production [2][3] - The campaign was supported by the Government of Québec, and the results will be used to update resource estimates for the project [3][4] Company Overview - NioBay Metals Inc. holds a 72.5% interest in the Crevier Project, located in Québec, and aims to develop mines with low carbon consumption and responsible environmental practices [1][20] - The company also has a 100% interest in the James Bay Niobium Project in Ontario, emphasizing the importance of Indigenous community participation in its operations [20] Drill Campaign Details - The 2025 drill campaign consisted of 15 holes covering 3,324 meters, designed to verify mineralization continuity [3] - The campaign confirmed the presence of mineralized zones, with results indicating various percentages of Nb2O5 across multiple drill holes [5][7] - Bulk sampling of over 140 tonnes of rock has been completed for further mineralogical testing [4][6] Mineralization Results - The drill results showed significant intercepts of niobium and tantalum, with various lengths and grades reported [5][8] - Notable intercepts include lengths of up to 19.85 meters with Nb2O5 grades reaching 0.3541% [5][14] - The results will contribute to a comprehensive resource estimate update for the Crevier Project [3][4] Future Plans - NioBay intends to utilize the winter season to advance work on the James Bay Niobium property while continuing discussions with potential customers for niobium oxide [2][3] - The company is focused on producing materials that meet the specific needs of battery manufacturers, indicating a strategic direction towards the energy sector [2][3]

Revenue Performance - Product revenue increased by $0.5 million, or 100%, to $0.5 million for the three months ended September 30, 2025, with revenue derived from the wound care business sold to a Chinese distributor[216] - Product revenue increased by $0.5 million, or 100%, to $0.5 million for the nine months ended September 30, 2025, with revenue from the wound care business sold to a Chinese distributor[225] Expenses - General and administrative expenses decreased by $0.5 million, or 29%, to $1.2 million for the three months ended September 30, 2025, primarily due to reduced outside services costs related to strategic initiatives[217] - General and administrative expenses rose by $0.2 million, or 3%, to $5.8 million for the nine months ended September 30, 2025, primarily due to increased outside services costs related to strategic initiatives[226] - Total operating expenses decreased by $405 thousand, or 24%, to $1.298 million for the three months ended September 30, 2025[214] - Total operating expenses increased by $868 thousand, or 15%, to $6.5 million for the nine months ended September 30, 2025[224] Net Income and Loss - Net loss from continuing operations was $1.333 million for the three months ended September 30, 2025, a decrease of $521 thousand, or 28%, compared to the prior year[214] - Net cash used in operating activities from continuing operations was $6.2 million for the nine months ended September 30, 2025, primarily due to a net loss from continuing operations of $6.6 million[233] - Net income from discontinued operations decreased by $602 thousand, or 94%, to $40 thousand for the three months ended September 30, 2025[214] - Net income from discontinued operations increased significantly to $11.1 million for the nine months ended September 30, 2025, compared to $841 thousand in the same period of 2024, representing a 1,213% increase[224] Asset Impairment - The Company recorded an impairment of $87 thousand for long-lived assets during the three months ended September 30, 2025[218] - The company recorded an impairment of long-lived assets totaling $676 thousand during the nine months ended September 30, 2025[227] Cash and Financing - Cash and cash equivalents increased to $2.3 million as of September 30, 2025, compared to $430 thousand as of December 31, 2024[232] - Net cash used in financing activities from continuing operations was $3.2 million for the nine months ended September 30, 2025, including $2.0 million in cash payments to repurchase outstanding warrants[236] Compliance and Future Outlook - The Company received notification from NYSE American on April 18, 2024, regarding non-compliance with stockholders' equity requirements, which was later resolved by October 20, 2025[205][207] - The Company believes existing cash and cash equivalents will be sufficient to meet planned operating expenses at least through November 7, 2026[208] - The Avenova Asset Divestiture and PhaseOne Divestiture were completed in January 2025, impacting the financial results significantly[205][214] - The Company is evaluating opportunities within emerging financial infrastructure and network-based markets, including select blockchain-based assets[204] Tax and Off-Balance Sheet Arrangements - The company had net operating loss carryforwards of $153.7 million for federal income tax purposes as of December 31, 2024[239] - The company has no off-balance sheet arrangements as of September 30, 2025[242]

Core Points - NovaBay Pharmaceuticals has regained compliance with the NYSE American's continued listing standards as of October 20, 2025 [1][4] - The company was previously notified of non-compliance on April 18, 2024, and May 28, 2024, due to insufficient stockholders' equity [2] - NovaBay raised approximately $6.0 million through the issuance of pre-funded warrants and an additional $2.15 million from the sale of Series E non-voting convertible preferred stock, bringing its stockholders' equity above the required $6 million [3] Company Background - NovaBay Pharmaceuticals focuses on the development and sale of scientifically created and clinically proven products in eyecare, wound care, and skin care [5]